
P Couvreur

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1418718/publications.pdf Version: 2024-02-01



P COUVEFUE

#	Article	IF	CITATIONS
1	Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 2013, 12, 991-1003.	13.3	5,084
2	Porous metal–organic-framework nanoscale carriers as a potential platform for drug deliveryÂand imaging. Nature Materials, 2010, 9, 172-178.	13.3	3,629
3	Metal–Organic Frameworks in Biomedicine. Chemical Reviews, 2012, 112, 1232-1268.	23.0	3,593
4	Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 2002, 54, 631-651.	6.6	2,520
5	Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications. Chemical Reviews, 2012, 112, 5818-5878.	23.0	1,769
6	Nanocarriers' entry into the cell: relevance to drug delivery. Cellular and Molecular Life Sciences, 2009, 66, 2873-2896.	2.4	1,300
7	Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chemical Society Reviews, 2013, 42, 1147-1235.	18.7	1,104
8	BioMOFs: Metal–Organic Frameworks for Biological and Medical Applications. Angewandte Chemie - International Edition, 2010, 49, 6260-6266.	7.2	1,074
9	Nanotechnology: Intelligent Design to Treat Complex Disease. Pharmaceutical Research, 2006, 23, 1417-1450.	1.7	858
10	Nanoparticles in cancer therapy and diagnosis. Advanced Drug Delivery Reviews, 2012, 64, 24-36.	6.6	642
11	Nanoparticles in drug delivery: Past, present and future. Advanced Drug Delivery Reviews, 2013, 65, 21-23.	6.6	569
12	Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomedicine and Pharmacotherapy, 2002, 56, 215-222.	2.5	490
13	Design of Folic Acid onjugated Nanoparticles for Drug Targeting. Journal of Pharmaceutical Sciences, 2000, 89, 1452-1464.	1.6	472
14	Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Advanced Drug Delivery Reviews, 2003, 55, 519-548.	6.6	463
15	Nanoparticles of Metalâ€Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine. Advanced Materials, 2018, 30, e1707365.	11.1	459
16	Polysaccharide-decorated nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 58, 327-341.	2.0	441
17	Folate-Conjugated Iron Oxide Nanoparticles for Solid Tumor Targeting as Potential Specific Magnetic Hyperthermia Mediators: Synthesis, Physicochemical Characterization, and in Vitro Experiments. Bioconjugate Chemistry, 2005, 16, 1181-1188.	1.8	439
18	Nanocapsule Technology: A Review. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 99-134.	1.2	435

#	Article	IF	CITATIONS
19	Nanotheranostics for personalized medicine. Advanced Drug Delivery Reviews, 2012, 64, 1394-1416.	6.6	408
20	Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceutical Research, 2001, 18, 1157-1166.	1.7	405
21	Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. Journal of Pharmacy and Pharmacology, 2011, 31, 331-332.	1.2	396
22	Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. Journal of Controlled Release, 1999, 60, 121-128.	4.8	369
23	Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. International Journal of Antimicrobial Agents, 2000, 13, 155-168.	1.1	365
24	Development of a New Drug Carrier Made from Alginate. Journal of Pharmaceutical Sciences, 1993, 82, 912-917.	1.6	340
25	New Approach for Oral Administration of Insulin With Polyalkylcyanoacrylate Nanocapsules as Drug Carrier. Diabetes, 1988, 37, 246-251.	0.3	337
26	Nanoprecipitation and the "Ouzo effect― Application to drug delivery devices. Advanced Drug Delivery Reviews, 2014, 71, 86-97.	6.6	318
27	In depth analysis of the in vivo toxicity of nanoparticles of porous iron(iii) metal–organic frameworks. Chemical Science, 2013, 4, 1597.	3.7	313
28	Self-Assembled Multicompartment Liquid Crystalline Lipid Carriers for Protein, Peptide, and Nucleic Acid Drug Delivery. Accounts of Chemical Research, 2011, 44, 147-156.	7.6	297
29	Colloidal carriers and blood–brain barrier (BBB) translocation: A way to deliver drugs to the brain?. International Journal of Pharmaceutics, 2005, 298, 274-292.	2.6	289
30	Pharmacokinetics and distribution of a biodegradable drug-carrier. International Journal of Pharmaceutics, 1983, 15, 335-345.	2.6	287
31	Squalenoyl Nanomedicines as Potential Therapeutics. Nano Letters, 2006, 6, 2544-2548.	4.5	281
32	Squalene: A natural triterpene for use in disease management and therapy. Advanced Drug Delivery Reviews, 2009, 61, 1412-1426.	6.6	281
33	Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. Journal of Neurochemistry, 2005, 93, 279-289.	2.1	280
34	Development and Brain Delivery of Chitosanâ ^{~^} PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26. Bioconjugate Chemistry, 2005, 16, 1503-1511.	1.8	279
35	Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials, 1984, 5, 65-68.	5.7	266
36	Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections. International Journal of Antimicrobial Agents, 2014, 43, 485-496.	1.1	265

#	Article	IF	CITATIONS
37	II. Clutamine and glutamate. Biomedicine and Pharmacotherapy, 2002, 56, 446-457.	2.5	264
38	Optimisation of the synthesis of MOF nanoparticles made of flexible porous iron fumarate MIL-88A. Journal of Materials Chemistry, 2011, 21, 2220-2227.	6.7	263
39	Prodrug-based intracellular delivery of anticancer agents. Advanced Drug Delivery Reviews, 2011, 63, 3-23.	6.6	258
40	Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials, 2000, 21, 1-7.	5.7	256
41	Nano- and microparticles for the delivery of polypeptides and proteins. Advanced Drug Delivery Reviews, 1993, 10, 141-162.	6.6	250
42	Recent trends in the design of anticancer polymer prodrug nanocarriers. Polymer Chemistry, 2014, 5, 1529-1544.	1.9	246
43	Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. Journal of Controlled Release, 2003, 93, 151-160.	4.8	243
44	Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 521-540.	1.7	240
45	Poly(ethylene glycol)-Coated Hexadecylcyanoacrylate Nanospheres Display a Combined Effect for Brain Tumor Targeting. Journal of Pharmacology and Experimental Therapeutics, 2002, 303, 928-936.	1.3	237
46	Nanocapsules as carriers for oral peptide delivery. Journal of Controlled Release, 1990, 13, 233-239.	4.8	229
47	Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nature Nanotechnology, 2014, 9, 1054-1062.	15.6	207
48	"Smart―delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Advanced Drug Delivery Reviews, 2004, 56, 931-946.	6.6	201
49	Toxicity of Polyalkylcyanoacrylate Nanoparticles II: Doxorubicin-Loaded Nanoparticles. Journal of Pharmaceutical Sciences, 1982, 71, 790-792.	1.6	199
50	Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology, 2005, 42, 736-743.	1.8	196
51	Visualization of in vitro protein-rejecting properties of PEGylated stealth® polycyanoacrylate nanoparticles. Biomaterials, 1999, 20, 1269-1275.	5.7	195
52	I. Arginine. Biomedicine and Pharmacotherapy, 2002, 56, 439-445.	2.5	194
53	Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials, 2003, 24, 4529-4537.	5.7	182
54	A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E217-26.	3.3	182

#	Article	IF	CITATIONS
55	The Design of Nanoparticles Obtained by Solvent Evaporation:  A Comprehensive Study. Langmuir, 2003, 19, 9504-9510.	1.6	180
56	Nanoparticulate systems for the delivery of antisense oligonucleotides. Advanced Drug Delivery Reviews, 2001, 47, 99-112.	6.6	179
57	Multicellular spheroid based on a triple co-culture: A novel 3D model to mimic pancreatic tumor complexity. Acta Biomaterialia, 2018, 78, 296-307.	4.1	179
58	Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. International Journal of Pharmaceutics, 2003, 254, 77-82.	2.6	178
59	Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials, 2006, 27, 108-118.	5.7	178
60	Cyclodextrins for drug delivery. Journal of Drug Targeting, 2010, 18, 645-656.	2.1	174
61	Translocation of Poly(ethylene glycol-co-hexadecyl)cyanoacrylate Nanoparticles into Rat Brain Endothelial Cells:Â Role of Apolipoproteins in Receptor-Mediated Endocytosis. Biomacromolecules, 2007, 8, 793-799.	2.6	172
62	A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection. Journal of Neuroscience, 2009, 29, 13761-13769.	1.7	169
63	Nanocapsules: A new type of lysosomotropic carrier. FEBS Letters, 1977, 84, 323-326.	1.3	167
64	Adsorption of Antineoplastic Drugs to Polyalkylcyanoacrylate Nanoparticles and Their Release in Calf Serum. Journal of Pharmaceutical Sciences, 1979, 68, 1521-1524.	1.6	165
65	PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease. ACS Nano, 2012, 6, 5897-5908.	7.3	164
66	Multicellular tumor spheroids: a relevant 3D model for the in vitro preclinical investigation of polymer nanomedicines. Polymer Chemistry, 2017, 8, 4947-4969.	1.9	161
67	New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes, 1988, 37, 246-251.	0.3	159
68	Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cellular and Molecular Life Sciences, 2007, 64, 356-364.	2.4	157
69	Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sciences, 1997, 61, 749-761.	2.0	154
70	Alkylcyanoacrylate drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. International Journal of Pharmaceutics, 1992, 84, 13-22.	2.6	153
71	Poly(alkyl cyanoacrylate) Nanospheres for Oral Administration of Insulin. Journal of Pharmaceutical Sciences, 1997, 86, 1403-1409.	1.6	149
72	Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides. Pharmaceutical Research, 2000, 17, 707-714.	1.7	149

#	Article	IF	CITATIONS
73	Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochemical Pharmacology, 1992, 44, 509-517.	2.0	148
74	Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading. International Journal of Pharmaceutics, 1990, 62, 1-7.	2.6	147
75	Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics. Current Pharmaceutical Design, 2005, 11, 2091-2105.	0.9	145
76	Toxicity of metal–organic framework nanoparticles: from essential analyses to potential applications. Chemical Society Reviews, 2022, 51, 464-484.	18.7	144
77	Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. British Journal of Cancer, 1997, 76, 198-205.	2.9	143
78	Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. European Journal of Neuroscience, 2002, 15, 1317-1326.	1.2	142
79	New self-assembled nanogels based on host–guest interactions: Characterization and drug loading. Journal of Controlled Release, 2006, 111, 316-324.	4.8	142
80	Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharmaceutical Research, 1992, 09, 441-449.	1.7	141
81	Squalene Based Nanocomposites: A New Platform for the Design of Multifunctional Pharmaceutical Theragnostics. ACS Nano, 2011, 5, 1513-1521.	7.3	141
82	Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Investigational New Drugs, 1992, 10, 191-199.	1.2	139
83	Tissue Distribution of Antitumor Drugs Associated with Polyalkylcyanoacrylate Nanoparticles. Journal of Pharmaceutical Sciences, 1980, 69, 199-202.	1.6	137
84	Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. Antimicrobial Agents and Chemotherapy, 1989, 33, 1540-1543.	1.4	135
85	Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip® system. Electrophoresis, 2007, 28, 2252-2261.	1.3	135
86	Fe3O4/chitosan nanocomposite for magnetic drug targeting to cancer. Journal of Materials Chemistry, 2012, 22, 7622.	6.7	132
87	Lipid Conjugated Oligonucleotides: A Useful Strategy for Delivery. Bioconjugate Chemistry, 2012, 23, 1091-1104.	1.8	131
88	Towards an Improved antiâ€HIV Activity of NRTI via Metal–Organic Frameworks Nanoparticles. Advanced Healthcare Materials, 2013, 2, 1630-1637.	3.9	130
89	Role of spleen macrophages in the clearance of scrapie agent early in pathogenesis. , 2000, 190, 495-502.		129
90	PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. Journal of Neuroscience Methods, 2001, 111, 151-155.	1.3	129

#	Article	IF	CITATIONS
91	Cyclodextrin and Polysaccharide-Based Nanogels: Entrapment of Two Hydrophobic Molecules, Benzophenone and Tamoxifen. Biomacromolecules, 2009, 10, 547-554.	2.6	129
92	In vitro model for the degradation of alkylcyanoacrylate nanoparticles. Biomaterials, 1990, 11, 590-595.	5.7	128
93	Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. European Journal of Cancer, 1994, 30, 89-93.	1.3	128
94	Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. European Journal of Immunology, 2004, 34, 3702-3712.	1.6	128
95	Palladium: a future key player in the nanomedical field?. Chemical Science, 2015, 6, 2153-2157.	3.7	128
96	Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharmaceutical Research, 1998, 15, 550-556.	1.7	127
97	Versatile and Efficient Targeting Using a Single Nanoparticulate Platform: Application to Cancer and Alzheimer's Disease. ACS Nano, 2012, 6, 5866-5879.	7.3	127
98	Polysaccharides Grafted with Polyesters: Novel Amphiphilic Copolymers for Biomedical Applications. Macromolecules, 2002, 35, 9861-9867.	2.2	124
99	Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemotherapy and Pharmacology, 1990, 26, 13-18.	1.1	123
100	Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. Journal of Controlled Release, 1998, 53, 137-143.	4.8	123
101	Cationic Vectors in Ocular Drug Delivery. Journal of Drug Targeting, 2004, 12, 623-633.	2.1	122
102	Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharmaceutical Research, 1994, 11, 1370-1378.	1.7	121
103	Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: Increased efficiency against an experimental tumor. European Journal of Cancer, 1980, 16, 1441-1445.	1.0	120
104	EWS Fli-1 Antisense Nanocapsules Inhibits Ewing Sarcoma-Related Tumor in Mice. Biochemical and Biophysical Research Communications, 2000, 279, 401-406.	1.0	119
105	Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. International Journal of Pharmaceutics, 2005, 298, 378-383.	2.6	118
106	A Smart Metal–Organic Framework Nanomaterial for Lung Targeting. Angewandte Chemie - International Edition, 2017, 56, 15565-15569.	7.2	118
107	Temperature-dependent rheological behavior of Pluronic F-127 aqueous solutions. International Journal of Pharmaceutics, 1987, 39, 121-127.	2.6	116
108	Disposition Kinetics and Oral Bioavailability of Vincamine-Loaded Polyalkyl Cyanoacrylate Nanoparticles. Journal of Pharmaceutical Sciences, 1986, 75, 955-958.	1.6	115

#	Article	IF	CITATIONS
109	Squalenoylation: A generic platform for nanoparticular drug delivery. Journal of Controlled Release, 2012, 161, 609-618.	4.8	115
110	A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. Journal of Controlled Release, 2007, 124, 20-27.	4.8	114
111	Discovery of New Hexagonal Supramolecular Nanostructures Formed by Squalenoylation of an Anticancer Nucleoside Analogue. Small, 2008, 4, 247-253.	5.2	114
112	Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing mice. Cancer Chemotherapy and Pharmacology, 1990, 26, 122-126.	1.1	113
113	Uptake of doxorubicin from loaded nanoparticles in multidrug-resistant leukemic murine cells. Cancer Chemotherapy and Pharmacology, 1994, 33, 504-508.	1.1	113
114	Self-Assembled Squalenoylated Penicillin Bioconjugates: An Original Approach for the Treatment of Intracellular Infections. ACS Nano, 2012, 6, 3820-3831.	7.3	112
115	Nanotechnology for therapy and imaging of liver diseases. Journal of Hepatology, 2011, 55, 1461-1466.	1.8	111
116	Polymer nanocarriers for the delivery of small fragments of nucleic acids: Oligonucleotides and siRNA. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 490-504.	2.0	110
117	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 609-618.	1.7	109
118	Novel core(polyester)-shell(polysaccharide) nanoparticles: protein loading and surface modification with lectins. Journal of Controlled Release, 2003, 92, 103-112.	4.8	108
119	Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharmaceutical Research, 1991, 08, 1079-1086.	1.7	107
120	Toxicity of Polyalkylcyanoacrylate Nanoparticles I: Free Nanoparticles. Journal of Pharmaceutical Sciences, 1982, 71, 786-790.	1.6	106
121	The Effect of Site of Administration in the Gastrointestinal Tract on the Absorption of Insulin from Nanocapsules in Diabetic Rats. Journal of Pharmacy and Pharmacology, 2011, 43, 1-5.	1.2	106
122	Advanced nanomedicines for the treatment of inflammatory diseases. Advanced Drug Delivery Reviews, 2020, 157, 161-178.	6.6	105
123	Multiple emulsion technology for the design of microspheres containing peptides and oligopeptides. Advanced Drug Delivery Reviews, 1997, 28, 85-96.	6.6	104
124	Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides. Pharmaceutical Research, 1998, 15, 1364-1369.	1.7	102
125	Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. International Journal of Pharmaceutics, 2007, 344, 71-77.	2.6	102
126	Novel Approaches to Deliver Gemcitabine to Cancers. Current Pharmaceutical Design, 2008, 14, 1124-1137.	0.9	101

#	Article	IF	CITATIONS
127	Novel Polysaccharide-Decorated Poly(Isobutyl Cyanoacrylate) Nanoparticles. Pharmaceutical Research, 2003, 20, 1786-1793.	1.7	100
128	Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. International Journal of Nanomedicine, 2007, 2, 609-22.	3.3	100
129	In Vivo Uptake of Polyisobutyl Cyanoacrylate Nanoparticles by Rat Liver Kupffer, Endothelial, andParenchymal Cells. Journal of Pharmaceutical Sciences, 1984, 73, 980-982.	1.6	99
130	Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives. Journal of Controlled Release, 1991, 17, 187-198.	4.8	99
131	Highâ€Relaxivity Magnetic Resonance Imaging (MRI) Contrast Agent Based on Supramolecular Assembly between a Gadolinium Chelate, a Modified Dextran, and Polyâ€Î²â€€yclodextrin. Chemistry - A European Journal, 2008, 14, 4551-4561.	1.7	99
132	Negative preclinical results with stealth® nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. Journal of Controlled Release, 2004, 100, 29-40.	4.8	97
133	A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cellular and Molecular Life Sciences, 2005, 62, 1400-1408.	2.4	97
134	Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Research, 2012, 40, 1891-1903.	6.5	97
135	Systemically Administered Brain-Targeted Nanoparticles Transport Peptides across the Blood—Brain Barrier and Provide Neuroprotection. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 469-475.	2.4	97
136	Small-Angle Neutron and X-ray Scattering from Amphiphilic Stimuli-Responsive Diamond-Type Bicontinuous Cubic Phase. Journal of the American Chemical Society, 2007, 129, 13474-13479.	6.6	96
137	Porous metal organic framework nanoparticles to address the challenges related to busulfan encapsulation. Nanomedicine, 2011, 6, 1683-1695.	1.7	95
138	Doxorubicin-Loaded Nanoparticles: Increased Efficiency in Murine Hepatic Metastases. Selective Cancer Therapeutics, 1989, 5, 1-11.	0.5	94
139	Spongelike Alginate Nanoparticles as a New Potential System for the Delivery of Antisense Oligonucleotides. Oligonucleotides, 1999, 9, 301-312.	4.4	94
140	Lipid prodrug nanocarriers in cancer therapy. Journal of Controlled Release, 2015, 208, 25-41.	4.8	94
141	The Effect of Suture Technique on Adhesion Formation after Flexor Tendon Repair for Partial Lacerations in a Canine Model. Journal of Trauma, 2001, 51, 917-921.	2.3	93
142	Efficacy of siRNA Nanocapsules Targeted Against the EWS–Fli1 Oncogene in Ewing Sarcoma. Pharmaceutical Research, 2006, 23, 892-900.	1.7	93
143	Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Progress in Retinal and Eye Research, 2000, 19, 131-147.	7.3	91
144	Synthesis of poly(alkyl cyanoacrylate)â€based colloidal nanomedicines. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 111-127.	3.3	91

#	Article	IF	CITATIONS
145	Innovative nanotechnologies forÂtheÂdelivery ofÂoligonucleotides andÂsiRNA. Biomedicine and Pharmacotherapy, 2006, 60, 607-620.	2.5	88
146	Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 841-849.	1.7	88
147	Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochemical and Biophysical Research Communications, 1992, 183, 879-885.	1.0	87
148	A Smart Metal–Organic Framework Nanomaterial for Lung Targeting. Angewandte Chemie, 2017, 129, 15771-15775.	1.6	87
149	Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice. Drug Metabolism and Disposition, 2008, 36, 1570-1577.	1.7	86
150	DNA/Fusogenic Lipid Nanocarrier Assembly: Millisecond Structural Dynamics. Journal of Physical Chemistry Letters, 2013, 4, 1959-1964.	2.1	86
151	Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery. Nature Communications, 2017, 8, 15678.	5.8	86
152	Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway. Journal of Controlled Release, 2010, 147, 163-170.	4.8	85
153	Spontaneous association of hydrophobized dextran and poly-β-cyclodextrin into nanoassemblies Journal of Colloid and Interface Science, 2007, 307, 83-93.	5.0	84
154	Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro. Journal of Controlled Release, 2000, 68, 283-289.	4.8	83
155	Novel self-assembling nanogels: Stability and lyophilisation studies. International Journal of Pharmaceutics, 2007, 332, 185-191.	2.6	83
156	Nanoparticles with Inâ€Vivo Anticancer Activity from Polymer Prodrug Amphiphiles Prepared by Living Radical Polymerization. Angewandte Chemie - International Edition, 2013, 52, 1678-1682.	7.2	83
157	Small-Angle X-ray Scattering Investigations of Biomolecular Confinement, Loading, and Release from Liquid-Crystalline Nanochannel Assemblies. Journal of Physical Chemistry Letters, 2012, 3, 445-457.	2.1	81
158	Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations. International Journal of Pharmaceutics, 1990, 58, 115-122.	2.6	80
159	Synthesis of a Novel Poly(MePEG cyanoacrylate-co-alkyl cyanoacrylate) Amphiphilic Copolymer for Nanoparticle Technology. Macromolecules, 1997, 30, 846-851.	2.2	80
160	Novel polyester-polysaccharide nanoparticles. Pharmaceutical Research, 2003, 20, 1284-1292.	1.7	80
161	Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process. Journal of Biomedical Materials Research Part B, 1993, 27, 1019-1028.	3.0	79
162	Increased bone marrow toxicity of doxorubicin bound to nanoparticles. European Journal of Cancer, 1994, 30, 820-826.	1.3	79

#	Article	IF	CITATIONS
163	Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. International Journal of Pharmaceutics, 2001, 214, 37-42.	2.6	79
164	Radical Emulsion Polymerization of Alkylcyanoacrylates Initiated by the Redox System Dextranâ^'Cerium(IV) under Acidic Aqueous Conditions. Macromolecules, 2003, 36, 6018-6027.	2.2	79
165	Physicochemical and Morphological Characterization of Polyisobutyl Cyanoacrylate Nanocapsules. Journal of Pharmaceutical Sciences, 1986, 75, 361-364.	1.6	77
166	Study of the mechanisms of formation of nanoparticles and nanocapsules of polyisobutyl-2-cyanoacrylate. International Journal of Pharmaceutics, 1993, 100, 55-64.	2.6	77
167	Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. Science Advances, 2020, 6, eaaz5466.	4.7	77
168	Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials, 2004, 25, 3081-3086.	5.7	76
169	Long-Living Intermediates during a Lamellar to a Diamond-Cubic Lipid Phase Transition: A Small-Angle X-Ray Scattering Investigation. Langmuir, 2009, 25, 3734-3742.	1.6	76
170	Specific Antitumor Targetable β-Cyclodextrinâ^'Poly(ethylene Glycol)â^'Folic Acid Drug Delivery Bioconjugate. Bioconjugate Chemistry, 2004, 15, 997-1004.	1.8	75
171	Detailed Structure of Diamond-Type Lipid Cubic Nanoparticles. Journal of the American Chemical Society, 2006, 128, 5813-5817.	6.6	75
172	Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases. Progress in Solid State Chemistry, 2006, 34, 231-235.	3.9	75
173	New magnetic drug carrier. Journal of Pharmacy and Pharmacology, 2011, 35, 59-61.	1.2	75
174	Synthesis, Characterization, and in Vivo Delivery of siRNA-Squalene Nanoparticles Targeting Fusion Oncogene in Papillary Thyroid Carcinoma. Journal of Medicinal Chemistry, 2011, 54, 4067-4076.	2.9	75
175	Development of a nanoparticle controlled-release formulation for human use. Journal of Controlled Release, 1986, 3, 205-210.	4.8	74
176	Preclinical Toxicology (Subacute and Acute) and Efficacy of a New Squalenoyl Gemcitabine Anticancer Nanomedicine. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 484-490.	1.3	73
177	Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. , 1996, 31, 401-408.		72
178	Novel Nanoassemblies Composed of Squalenoylâ^'Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation. Bioconjugate Chemistry, 2010, 21, 1349-1361.	1.8	72
179	Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude mice. Antimicrobial Agents and Chemotherapy, 1988, 32, 1204-1207.	1.4	71
180	Development of sterically stabilized poly(isobutyl 2-cyanoacrylate) nanoparticles by chemical coupling of poly(ethylene glycol). , 1997, 34, 317-326.		71

#	Article	IF	CITATIONS
181	Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood–brain barrier. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 463-474.	3.3	71
182	Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharmaceutical Research, 1996, 13, 38-43.	1.7	70
183	Facile Synthesis of Innocuous Comb-Shaped Polymethacrylates with PEG Side Chains by Nitroxide-Mediated Radical Polymerization in Hydroalcoholic Solutions. Macromolecules, 2010, 43, 9291-9303.	2.2	70
184	Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharmaceutical Research, 1999, 16, 1710-1716.	1.7	69
185	GraftFast Surface Engineering to Improve MOF Nanoparticles Furtiveness. Small, 2018, 14, e1801900.	5.2	69
186	Magnetically responsive microspheres for the pulsed delivery of insulin. Life Sciences, 1988, 42, 1521-1528.	2.0	68
187	First peptide/protein PEGylation with functional polymers designed by nitroxide-mediated polymerization. Polymer Chemistry, 2011, 2, 1523.	1.9	68
188	An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance. Scientific Reports, 2015, 5, 13500.	1.6	68
189	Reversion of multidrug resistance using nanoparticles in vitro: Influence of the nature of the polymer. International Journal of Pharmaceutics, 1996, 138, 237-246.	2.6	67
190	Evaluation of hepatic antioxidant systems after intravenous administration of polymeric nanoparticles. Biomaterials, 1997, 18, 511-517.	5.7	67
191	Novel PEGylated Nanoassemblies Made of Selfâ€Assembled Squalenoyl Nucleoside Analogues. Advanced Functional Materials, 2008, 18, 3715-3725.	7.8	67
192	Therapeutic Modalities of Squalenoyl Nanocomposites in Colon Cancer: An Ongoing Search for Improved Efficacy. ACS Nano, 2014, 8, 2018-2032.	7.3	67
193	Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharmaceutical Research, 2003, 20, 1071-1084.	1.7	66
194	Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chemistry and Physics of Lipids, 2004, 131, 1-13.	1.5	66
195	Interactions of anticancer drugs with biomembranes: What can we learn from model membranes?. Journal of Controlled Release, 2014, 190, 127-138.	4.8	66
196	Efficient "green―encapsulation of a highly hydrophilic anticancer drug in metal–organic framework nanoparticles. Journal of Drug Targeting, 2015, 23, 759-767.	2.1	66
197	Attachment of antibiotics to nanoparticles: preparation, drug-release and antimicrobial activity in vitro. International Journal of Pharmaceutics, 1987, 35, 121-127.	2.6	65
198	Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. Journal of Controlled Release, 1998, 56, 23-32.	4.8	65

#	Article	IF	CITATIONS
199	Insulin-loaded nanocapsules for oral administration: In vitro and in vivo investigation. Drug Development Research, 2000, 49, 109-117.	1.4	65
200	Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy. Cancer Letters, 2013, 334, 346-353.	3.2	65
201	Nanoparticles as microcarriers for anticancer drugs. Advanced Drug Delivery Reviews, 1990, 5, 209-230.	6.6	64
202	Nanoparticles as carriers for growth hormone releasing factor. Journal of Controlled Release, 1991, 15, 3-13.	4.8	64
203	Effect of nanoparticle-bound ampicillin on the survival of Listeria monocytogenes in mouse peritoneal macrophages. Journal of Antimicrobial Chemotherapy, 1992, 30, 173-179.	1.3	64
204	Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharmaceutical Research, 1992, 09, 1534-1539.	1.7	64
205	Study of the mechanism of insulin encapsulation in poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. , 1999, 47, 568-576.		63
206	Novel composite core-shell nanoparticles as busulfan carriers. Journal of Controlled Release, 2006, 111, 271-280.	4.8	63
207	In vivo behavior of MIL-100 nanoparticles at early times after intravenous administration. International Journal of Pharmaceutics, 2016, 511, 1042-1047.	2.6	63
208	Molecular weights of free and drug-loaded nanoparticles. Pharmaceutical Research, 1985, 02, 36-41.	1.7	62
209	Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharmaceutical Research, 1993, 10, 1427-1433.	1.7	62
210	Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Investigative Ophthalmology and Visual Science, 2002, 43, 253-9.	3.3	62
211	A new painkiller nanomedicine to bypass the blood-brain barrier and the use of morphine. Science Advances, 2019, 5, eaau5148.	4.7	61
212	A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. International Journal of Pharmaceutics, 2005, 298, 310-314.	2.6	60
213	A Squalene-Based Nanomedicine for Oral Treatment of Colon Cancer. Cancer Research, 2017, 77, 2964-2975.	0.4	60
214	Nanomedicines for Pediatric Cancers. ACS Nano, 2018, 12, 7482-7496.	7.3	60
215	SG1 Nitroxide-Mediated Polymerization of Isoprene: Alkoxyamine Structure/Control Relationship and α,ω–Chain-End Functionalization. Macromolecules, 2011, 44, 9230-9238.	2.2	59
216	A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles' characteristics and efficacy of intracellular delivery. Artificial Cells, Nanomedicine and Biotechnology, 2017, 45, 1657-1664.	1.9	59

#	Article	IF	CITATIONS
217	Selfâ€assembling cyclodextrin based hydrogels for the sustained delivery of hydrophobic drugs. Journal of Biomedical Materials Research - Part A, 2008, 86A, 736-748.	2.1	58
218	Comblike Polymethacrylates with Poly(ethylene glycol) Side Chains via Nitroxide-Mediated Controlled Free-Radical Polymerization. Macromolecules, 2008, 41, 3758-3761.	2.2	58
219	Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infection and Immunity, 1997, 65, 853-857.	1.0	58
220	Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length. International Journal of Pharmaceutics, 1992, 84, 1-11.	2.6	57
221	Solvent selection causes remarkable shifts of the "Ouzo region―for poly(lactide-co-glycolide) nanoparticles prepared by nanoprecipitation. Nanoscale, 2015, 7, 9215-9221.	2.8	57
222	Characterization of V3 BRU peptide-loaded small PLGA microspheres prepared by a (w1/o)w2 emulsion solvent evaporation method. International Journal of Pharmaceutics, 1994, 111, 137-145.	2.6	56
223	Cells Involved in the Capture of Nanoparticles in Hematopoietic Organs. Journal of Pharmaceutical Sciences, 1996, 85, 944-950.	1.6	56
224	Measurement of the Density of Polymeric Nanoparticulate Drug Carriers by Isopycnic Centrifugation. Journal of Nanoparticle Research, 1999, 1, 411-418.	0.8	56
225	Design of triptorelin loaded nanospheres for transdermal iontophoretic administration. International Journal of Pharmaceutics, 2001, 214, 31-35.	2.6	56
226	Encapsulation of mono- and oligo-nucleotides into aqueous-core nanocapsules in presence of various water-soluble polymers. International Journal of Pharmaceutics, 2007, 331, 148-152.	2.6	56
227	Colloidal stability of ultrasmall superparamagnetic iron oxide (USPIO) particles with different coatings. International Journal of Pharmaceutics, 2007, 331, 197-203.	2.6	56
228	Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy. Chemical Communications, 2014, 50, 5336-5338.	2.2	56
229	A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus. Journal of Virology, 2015, 89, 11129-11143.	1.5	56
230	Light sheet fluorescence microscopy versus confocal microscopy: in quest of a suitable tool to assess drug and nanomedicine penetration into multicellular tumor spheroids. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 195-203.	2.0	56
231	Characterization of a new ocular delivery system based on a dispersion of liposomes in a thermosensitive gel. International Journal of Pharmaceutics, 1998, 162, 119-127.	2.6	55
232	Anticancer Efficacy of Squalenoyl Gemcitabine Nanomedicine on 60 Human Tumor Cell Panel and on Experimental Tumor. Molecular Pharmaceutics, 2009, 6, 1526-1535.	2.3	55
233	Polymer Prodrug Nanoparticles Based on Naturally Occurring Isoprenoid for Anticancer Therapy. Biomacromolecules, 2013, 14, 2837-2847.	2.6	55
234	PEGylated squalenoyl-gemcitabine nanoparticles for the treatment ofÂglioblastoma. Biomaterials, 2016, 105, 136-144.	5.7	55

#	Article	IF	CITATIONS
235	Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). Journal of Controlled Release, 1998, 52, 131-139.	4.8	54
236	Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharmaceutical Research, 1999, 16, 37-41.	1.7	54
237	Encapsulation of antiviral nucleotide analogues azidothymidine-triphosphate and cidofovir in poly(iso-butylcyanoacrylate) nanocapsules. International Journal of Pharmaceutics, 2006, 324, 37-42.	2.6	54
238	Magnetoresponsive Squalenoyl Gemcitabine Composite Nanoparticles for Cancer Active Targeting. Langmuir, 2008, 24, 7512-7519.	1.6	54
239	Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. International Journal of Pharmaceutics, 2002, 242, 15-24.	2.6	53
240	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research, 2007, 36, e2-e2.	6.5	53
241	Superior Preclinical Efficacy of Gemcitabine Developed As Chitosan Nanoparticulate System. Biomacromolecules, 2011, 12, 97-104.	2.6	53
242	Evaluation of Liver Toxicological Effects Induced by Polyalkylcyanoacrylate Nanoparticles. Toxicology and Applied Pharmacology, 1995, 130, 272-279.	1.3	51
243	Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles. Pharmaceutical Research, 1995, 12, 85-87.	1.7	51
244	Role of gut macrophages in mice orally contaminated with scrapie or BSE. International Journal of Pharmaceutics, 2005, 298, 293-304.	2.6	51
245	Physico-chemical characterization of polysaccharide-coated nanoparticles. Journal of Controlled Release, 2005, 108, 97-111.	4.8	51
246	Nanotechnologies for the treatment of colon cancer: From old drugs to new hope. International Journal of Pharmaceutics, 2016, 514, 24-40.	2.6	51
247	Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosis. Antimicrobial Agents and Chemotherapy, 1991, 35, 770-772.	1.4	50
248	Submicron cationic emulsions as a new delivery system for oligonucleotides. Pharmaceutical Research, 1999, 16, 30-36.	1.7	50
249	New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid-β Peptide. Analytical Chemistry, 2010, 82, 10083-10089.	3.2	50
250	Comproportionation versus Disproportionation in the Initiation Step of Cu(0)-Mediated Living Radical Polymerization. Macromolecules, 2012, 45, 7388-7396.	2.2	50
251	Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles. Journal of Antimicrobial Chemotherapy, 1996, 37, 105-115.	1.3	49
252	Characterization and morphological analysis of a cholecystokinin derivative peptide-loaded poly(lactide-co-glycolide) microspheres prepared by a water-in-oil-in-water emulsion solvent evaporation method. Journal of Controlled Release, 1997, 43, 81-87.	4.8	49

#	Article	IF	CITATIONS
253	Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine. Journal of Drug Targeting, 2009, 17, 586-598.	2.1	49
254	Design attributes of long-circulating polymeric drug delivery vehicles. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 97, 304-317.	2.0	49
255	Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: carrier capacity and drug release. International Journal of Pharmaceutics, 1991, 70, 129-135.	2.6	48
256	Improving the Antitumor Activity of Squalenoylâ€Paclitaxel Conjugate Nanoassemblies by Manipulating the Linker between Paclitaxel and Squalene. Advanced Healthcare Materials, 2013, 2, 172-185.	3.9	48
257	Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor. Journal of Controlled Release, 2014, 192, 29-39.	4.8	48
258	Splenic trapping of nanoparticles: complementary approaches for in situ studies. Pharmaceutical Research, 1997, 14, 463-468.	1.7	47
259	Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharmaceutical Research, 2000, 17, 1124-1132.	1.7	47
260	Nanoencapsulation of a crystalline drug. International Journal of Pharmaceutics, 2005, 298, 323-327.	2.6	47
261	Hybrid polymer nanocapsules enhance in vitro delivery of azidothymidine-triphosphate to macrophages. Journal of Controlled Release, 2006, 116, 346-352.	4.8	47
262	Optimization of polyalkylcyanoacrylate nanoparticle preparation: Influence of sulfur dioxide and pH on nanoparticle characteristics. Journal of Colloid and Interface Science, 1992, 154, 77-86.	5.0	46
263	Physico-chemical characterization of insulin-loaded poly(isobutylcyanoacrylate) nanocapsules obtained by interfacial polymerization. International Journal of Pharmaceutics, 1999, 183, 63-66.	2.6	46
264	Simple and efficient copper metal-mediated synthesis of alkoxyamine initiators. Polymer Chemistry, 2011, 2, 1859.	1.9	46
265	Precise Engineering of Multifunctional PEGylated Polyester Nanoparticles for Cancer Cell Targeting and Imaging. Chemistry of Materials, 2014, 26, 1834-1847.	3.2	46
266	Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharmaceutical Research, 1994, 11, 38-46.	1.7	45
267	Changing the pH of the external aqueous phase may modulate protein entrapment and delivery from poly(lactide-co-glycolide) microspheres prepared by a w/o/w solvent evaporation method. Journal of Microencapsulation, 1998, 15, 421-430.	1.2	45
268	New Core-Shell Nanoparticules for the Intravenous Delivery of siRNA to Experimental Thyroid Papillary Carcinoma. Pharmaceutical Research, 2010, 27, 498-509.	1.7	45
269	Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharmaceutical Research, 1994, 11, 1160-1165.	1.7	44
270	Protein Driven Patterning of Self-Assembled Cubosomic Nanostructures:Â Long Oriented Nanoridges. Journal of Physical Chemistry B, 2005, 109, 3089-3093.	1.2	44

#	Article	IF	CITATIONS
271	Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chemical Communications, 2010, 46, 2602.	2.2	44
272	Tissue distribution of [3H]actinomycin D adsorbed on polybutylcyanoacrylate nanoparticles. International Journal of Pharmaceutics, 1980, 7, 45-53.	2.6	43
273	Preparation and characterization of novel poly(methylidene malonate 2.1.2.)-made nanoparticles. Pharmaceutical Research, 1994, 11, 1270-1277.	1.7	43
274	A comprehensive study of the spontaneous formation of nanoassemblies in water by a "lock-and-key― interaction between two associative polymers. Journal of Colloid and Interface Science, 2011, 354, 517-527.	5.0	43
275	Vidarabine-loaded nanoparticles: a physicochemical study. Pharmaceutical Research, 1990, 07, 736-741.	1.7	42
276	Intracellular targeting of antibiotics by means of biodegradable nanoparticles. Journal of Controlled Release, 1992, 19, 259-267.	4.8	42
277	Gliding resistance after repair of partially lacerated human flexor digitorum profundus tendon in vitro. Clinical Biomechanics, 2001, 16, 696-701.	0.5	42
278	Nanomedicines: A New Approach for the Treatment of Serious Diseases. Journal of Biomedical Nanotechnology, 2007, 3, 223-234.	0.5	42
279	Vitamin C–squalene bioconjugate promotes epidermal thickening and collagen production in human skin. Scientific Reports, 2020, 10, 16883.	1.6	42
280	Some parameters influencing cytotoxicity of free doxorubicin and doxorubicin-loaded nanoparticles in sensitive and multidrug resistant leucemic murine cells: incubation time, number of nanoparticles per cell. International Journal of Pharmaceutics, 1994, 102, 55-62.	2.6	41
281	Effect of polyisobutylcyanoacrylate nanoparticles and Lipofectin® loaded with oligonucleotides on cell viability and PKCα neosynthesis in HepG2 cells. Biochimie, 1998, 80, 969-976.	1.3	41
282	pH-sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples. Biochimica Et Biophysica Acta - Biomembranes, 1998, 1372, 301-310.	1.4	41
283	Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and <i>in vitro</i> antimicrobial activity. Journal of Microencapsulation, 1991, 8, 29-36.	1.2	40
284	Oral tolerance elicited in mice by β-lactoglobulin entrapped in biodegradable microspheres. Vaccine, 2000, 18, 1196-1202.	1.7	40
285	Therapeutic Potentialities of EWS-Fli-1 mRNA-Targeted Vectorized Antisense Oligonucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 72-77.	1.8	40
286	Synthesis of Highly Functionalized Poly(alkyl cyanoacrylate) Nanoparticles by Means of Click Chemistry. Macromolecules, 2008, 41, 8418-8428.	2.2	40
287	Novel Isoprenoyl Nanoassembled Prodrug for Paclitaxel Delivery. Bioconjugate Chemistry, 2013, 24, 1840-1849.	1.8	40
288	Self-Assembly of Squalene-Based Nucleolipids: Relating the Chemical Structure of the Bioconjugates to the Architecture of the Nanoparticles. Langmuir, 2013, 29, 14795-14803.	1.6	40

#	Article	IF	CITATIONS
289	Polyisobutylcyanoacrylate nanocapsules containing an aqueous core for the delivery of oligonucleotides. International Journal of Pharmaceutics, 2001, 214, 13-16.	2.6	39
290	Phospholipid hydrolysis in a pharmaceutical emulsion assessed by physicochemical parameters and a new analytical method. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 61, 69-76.	2.0	39
291	Bioadhesive Properties of Poly(alkylcyanoacrylate) Nanoparticles Coated with Polysaccharide. Journal of Nanoscience and Nanotechnology, 2006, 6, 3102-3109.	0.9	39
292	Quantification of fumaric acid in liver, spleen and urine by high-performance liquid chromatography coupled to photodiode-array detection. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 758-762.	1.4	39
293	Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Molecular Therapy, 2017, 25, 1596-1605.	3.7	39
294	The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. Journal of Antimicrobial Chemotherapy, 1994, 33, 509-522.	1.3	38
295	Study of the influence of several stabilizing agents on the entrapment and in vitro release of pBC 264 from poly(lactide-co-glycolide) microspheres prepared by a W/O/W solvent evaporation method. Pharmaceutical Research, 1996, 13, 1127-1129.	1.7	38
296	Comparison of the Ocular Distribution of a Model Oligonucleotide after Topical Instillation in Rabbits of Conventional and New Dosage Forms. Journal of Drug Targeting, 1998, 6, 309-313.	2.1	38
297	A polysorbate-based non-ionic surfactant can modulate loading and release of beta-lactoglobulin entrapped in multiphase poly(DL-lactide-co-glycolide) microspheres. Pharmaceutical Research, 1999, 16, 255-260.	1.7	38
298	pH-Sensitive liposomes as a carrier for oligonucleotides: a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in excess water. Biophysical Chemistry, 2000, 87, 127-137.	1.5	38
299	Nanoplumbers: biomaterials to fight cardiovascular diseases. Materials Today, 2018, 21, 122-143.	8.3	38
300	Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles. Journal of Controlled Release, 2019, 307, 302-314.	4.8	38
301	A new approach for the characterization of insoluble amphiphilic copolymers based on their emulsifying properties. Colloid and Polymer Science, 2004, 282, 1097-1104.	1.0	37
302	â€~Green' fluorine-free mesoporous iron(III) trimesate nanoparticles for drug delivery. Green Materials, 2013, 1, 209-217.	1.1	37
303	Liposomes, an Interesting Tool to Deliver a Bioenergetic Substrate (ATP),in Vitroandin VivoStudies. Journal of Drug Targeting, 1994, 2, 443-448.	2.1	36
304	Optimization of the encapsulation and release of β-lactoglobulin entrapped poly(dl-lactide-co-glycolide) microspheres. International Journal of Pharmaceutics, 1999, 183, 67-71.	2.6	36
305	Physicochemical Characteristics and Preliminary in Vivo Biological Evaluation of Nanocapsules Loaded with siRNA Targeting Estrogen Receptor Alpha. Biomacromolecules, 2008, 9, 2881-2890.	2.6	36
306	On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemotherapy and Pharmacology, 1996, 37, 556-560.	1.1	35

#	Article	lF	CITATIONS
307	Freeze-Drying of Composite Core-Shell Nanoparticles. Drug Development and Industrial Pharmacy, 2006, 32, 839-846.	0.9	35
308	Biological characterization of folic acid-conjugated poly(H2NPEGCA-co-HDCA) nanoparticles in cellular models. Journal of Drug Targeting, 2007, 15, 146-153.	2.1	35
309	Interaction of Self-Assembled Squalenoyl Gemcitabine Nanoparticles with Phospholipidâ^'Cholesterol Monolayers Mimicking a Biomembrane. Langmuir, 2011, 27, 4891-4899.	1.6	35
310	Peptide Conjugation: Before or After Nanoparticle Formation?. Bioconjugate Chemistry, 2014, 25, 1971-1983.	1.8	35
311	Protection of insulin from enzymatic degradation by its association to liposomes. International Journal of Pharmaceutics, 1985, 26, 251-257.	2.6	34
312	Biodegradable nanoparticles for subcutaneous administration of growth hormone releasing factor (hGRF). Journal of Controlled Release, 1992, 20, 67-77.	4.8	34
313	Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale, 2010, 2, 1521.	2.8	34
314	Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results. Journal of Materials Chemistry B, 2016, 4, 585-588.	2.9	34
315	A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles. Journal of Controlled Release, 2003, 92, 19-26.	4.8	33
316	Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2237-2240.	1.0	33
317	Squalenoyl nucleoside monophosphate nanoassemblies: New prodrug strategy for the delivery of nucleotide analogues. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2761-2764.	1.0	33
318	Interaction of a new anticancer prodrug, gemcitabine–squalene, with a model membrane. Biochimica Et Biophysica Acta - Biomembranes, 2010, 1798, 1522-1532.	1.4	33
319	Use of Solvent Effects to Improve Control Over Nitroxideâ€Mediated Polymerization of Isoprene. Macromolecular Rapid Communications, 2012, 33, 805-810.	2.0	33
320	Evaluation of brain-targeted chitosan nanoparticles through blood–brain barrier cerebral microvessel endothelial cells. Journal of Microencapsulation, 2017, 34, 659-666.	1.2	33
321	Sorptive properties of antibodies onto cyanoacrylic nanoparticles. International Journal of Pharmaceutics, 1988, 41, 181-187.	2.6	32
322	Mucosal immunogenicity elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly (d,l-lactide-co-glycolide) microspheres. Vaccine, 1998, 16, 685-691.	1.7	32
323	Polymer-Based Nanoparticles for the Delivery of Nucleoside Analogues. Journal of Nanoscience and Nanotechnology, 2006, 6, 2608-2617.	0.9	32
324	Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. Anti-Cancer Drugs, 2008, 19, 999-1006.	0.7	32

#	Article	IF	CITATIONS
325	Interaction of an anticancer drug, gemcitabine, with phospholipid bilayers. Journal of Thermal Analysis and Calorimetry, 2009, 98, 19-28.	2.0	32
326	Facile Synthesis of Multicompartment Micelles Based on Biocompatible Poly(3â€hydroxyalkanoate). Macromolecular Rapid Communications, 2013, 34, 362-368.	2.0	32
327	Transport Mechanisms of Squalenoyl-Adenosine Nanoparticles Across the Blood–Brain Barrier. Chemistry of Materials, 2015, 27, 3636-3647.	3.2	32
328	How can nanomedicines overcome cellular-based anticancer drug resistance?. Journal of Materials Chemistry B, 2016, 4, 5078-5100.	2.9	32
329	Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis. Journal of Microencapsulation, 1989, 6, 29-34.	1.2	31
330	Efficiency of liposomal ATP in cerebral ischemia: Bioavailability features. Brain Research Bulletin, 1991, 26, 339-342.	1.4	31
331	On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level. Biomedical Applications, 1997, 702, 181-191.	1.7	31
332	In vitro evaluation of nanoparticles spleen capture. Life Sciences, 1999, 64, 1329-1337.	2.0	31
333	Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sciences, 2000, 67, 1625-1637.	2.0	31
334	Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. Biomaterials, 2013, 34, 4831-4838.	5.7	31
335	Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A. Communications Biology, 2021, 4, 317.	2.0	31
336	Increased eytotoxicity of nanoparticle-carried Adriamycin in vitro and potentiation by verapamil and amiodarone. Biomaterials, 1989, 10, 553-556.	5.7	30
337	Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharmaceutical Research, 2003, 20, 1565-1567.	1.7	30
338	Simple Synthesis of Cladribine-Based Anticancer Polymer Prodrug Nanoparticles with Tunable Drug Delivery Properties. Chemistry of Materials, 2016, 28, 6266-6275.	3.2	30
339	Polyalkylcyanoacrylates as colloidal drug carriers. Critical Reviews in Therapeutic Drug Carrier Systems, 1988, 5, 1-20.	1.2	30
340	Stability of orosomucoid-coated polyisobutylcyanoacrylate nanoparticles in the presence of serum. Journal of Controlled Release, 1996, 40, 157-168.	4.8	29
341	Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella. Pharmaceutical Research, 1998, 15, 544-549.	1.7	29
342	Nanoparticles: heating tumors to death?. Nanomedicine, 2011, 6, 99-109.	1.7	29

#	Article	IF	CITATIONS
343	Nanomedicine as a promising approach for the treatment and diagnosis of brain diseases: The example of Alzheimer's disease. Annales Pharmaceutiques Francaises, 2013, 71, 225-233.	0.4	29
344	Rational design for multifunctional non-liposomal lipid-based nanocarriers for cancer management: theory to practice. Journal of Nanobiotechnology, 2013, 11, S6.	4.2	29
345	Towards improved HIV-microbicide activity through the co-encapsulation of NRTI drugs in biocompatible metal organic framework nanocarriers. Journal of Materials Chemistry B, 2017, 5, 8563-8569.	2.9	29
346	Low-Density Lipoproteins and Human Serum Albumin as Carriers of Squalenoylated Drugs: Insights from Molecular Simulations. Molecular Pharmaceutics, 2018, 15, 585-591.	2.3	29
347	Dual controlled delivery of squalenoyl-gemcitabine and paclitaxel using thermo-responsive polymeric micelles for pancreatic cancer. Journal of Materials Chemistry B, 2018, 6, 2230-2239.	2.9	29
348	Experience with doxorubicin-bound polyisohexylcyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. International Journal for Parasitology, 1993, 23, 427-429.	1.3	28
349	Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumoniae. Vaccine, 2000, 18, 2991-2998.	1.7	28
350	Significant Tumor Growth Inhibition from Naturally Occurring Lipid-Containing Polymer Prodrug Nanoparticles Obtained by the Drug-Initiated Method. Chemistry of Materials, 2014, 26, 3606-3609.	3.2	28
351	Squalenoylation of Chitosan: A Platform for Drug Delivery?. Biomacromolecules, 2015, 16, 2930-2939.	2.6	28
352	Structural Characterization of Ultrasmall Superparamagnetic Iron Oxide (USPIO) Particles in Aqueous Suspension by Energy Dispersive X-ray Diffraction (EDXD). Journal of the American Chemical Society, 2006, 128, 10054-10059.	6.6	27
353	Liposomally-entrapped ATP: Improved efficiency against experimental brain ischemia in the rat. Life Sciences, 1987, 40, 2011-2016.	2.0	26
354	The stenlying effect of high hydrostatic pressure on thermally and hydrolytically labile nanosized carriers. Pharmaceutical Research, 2003, 20, 674-683.	1.7	26
355	Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. International Journal of Pharmaceutics, 2007, 344, 62-70.	2.6	26
356	Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography–tandem mass spectrometry in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 71-78.	1.2	26
357	Squalenoyl Gemcitabine Monophosphate: Synthesis, Characterisation of Nanoassemblies and Biological Evaluation. European Journal of Organic Chemistry, 2011, 2011, 2615-2628.	1.2	26
358	Novel self assembling nanoparticles for the oral administration of fondaparinux: Synthesis, characterization and in vivo evaluation. Journal of Controlled Release, 2014, 194, 323-331.	4.8	26
359	Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. PLoS ONE, 2015, 10, e0125277.	1.1	26
360	Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. International Journal of Pharmaceutics, 2015, 482, 38-46.	2.6	26

#	Article	IF	CITATIONS
361	Protein-functionalized nanoparticles derived from end-functional polymers and polymer prodrugs for crossing the blood-brain barrier. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 70-82.	2.0	26
362	PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102125.	1.7	26
363	Isobutyl cyanoacrylate nanoparticles as a solid phase for an efficient immunoradiometric assay. Biomaterials, 1986, 7, 212-216.	5.7	25
364	Factors influencing the oligonucleotides release from O–W submicron cationic emulsions. Journal of Controlled Release, 2001, 70, 243-255.	4.8	25
365	Molecular Reactivity of Busulfan Through Its Experimental Electrostatic Properties in the Solid State. Pharmaceutical Research, 2004, 21, 598-607.	1.7	25
366	In Vivo Potentialities of EWS-Fli-1 Targeted Antisense Oligonucleotides-Nanospheres Complexes. Annals of the New York Academy of Sciences, 2005, 1058, 52-61.	1.8	25
367	Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid-l ² peptide and surface reorganization. International Journal of Pharmaceutics, 2011, 416, 453-460.	2.6	25
368	Liposomally entrapped adenosine triphosphate. Journal of Chromatography A, 1988, 440, 455-458.	1.8	24
369	Enhancing the tolerance of poly(isobutylcyanoacrylate) nanoparticles with a modular surface design. International Journal of Pharmaceutics, 2007, 338, 327-332.	2.6	24
370	Extracellular-protein-enhanced cellular uptake of squalenoyl gemcitabine from nanoassemblies. Soft Matter, 2010, 6, 5570.	1.2	24
371	Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections. Particle and Particle Systems Characterization, 2019, 36, 1800360.	1.2	24
372	Intracarotidal administration of liposomally-entrapped ATP : Improved efficiency against experimental brain ischemia. Pharmacological Research Communications, 1988, 20, 699-705.	0.2	23
373	On shelf stability of freeze-dried poly(methylidene malonate 2.1.2) nanoparticles. International Journal of Pharmaceutics, 1997, 148, 165-175.	2.6	23
374	Quantum dot-loaded PEGylated poly(alkyl cyanoacrylate) nanoparticles for in vitro and in vivo imaging. Soft Matter, 2011, 7, 6187.	1.2	23
375	Synthesis and physicochemical characterization of new squalenoyl amphiphilic gadolinium complexes as nanoparticle contrast agents. Organic and Biomolecular Chemistry, 2011, 9, 4367.	1.5	23
376	Multilamellar Nanoparticles Self-Assembled from Opposite Charged Blends: Insights from Mesoscopic Simulation. Journal of Physical Chemistry C, 2015, 119, 20649-20661.	1.5	23
377	Synthesis and in vitro study of a diglyceride prodrug of a peptide. Pharmaceutical Research, 1994, 11, 1082-1087.	1.7	22
378	Microcalorimetric investigation on the formation of supramolecular nanoassemblies of associative polymers loaded with gadolinium chelate derivatives. International Journal of Pharmaceutics, 2009, 379, 218-225.	2.6	22

#	Article	IF	CITATIONS
379	Unloaded polyisobutylcyanoacrylate nanoparticles: efficiency against bloodstream trypanosomes. Journal of Pharmacy and Pharmacology, 2011, 39, 650-652.	1.2	22
380	Pharmacokinetics, biodistribution and metabolism of squalenoyl adenosine nanoparticles in mice using dual radio-labeling and radio-HPLC analysis. Journal of Controlled Release, 2015, 212, 50-58.	4.8	22
381	In Vivo FRET Imaging to Predict the Risk Associated with Hepatic Accumulation of Squaleneâ€Based Prodrug Nanoparticles. Advanced Healthcare Materials, 2018, 7, 1700830.	3.9	22
382	A facile route to heterotelechelic polymer prodrug nanoparticles for imaging, drug delivery and combination therapy. Journal of Controlled Release, 2018, 286, 425-438.	4.8	22
383	REACTION OF N-BROMOSUCCINIMIDE WITH NITRILES. II.2, 3 ALIPHATIC NITRILES. Journal of Organic Chemistry, 1953, 18, 501-506.	1.7	21
384	Development of a Quantitative Polyacrylamide Gel Electrophoresis Analysis Using a Multichannel Radioactivity Counter for the Evaluation of Oligonucleotide-Bound Drug Carrier. Analytical Biochemistry, 1996, 240, 202-209.	1.1	21
385	New bicompartmental structures are observed when stearylamine is mixed with triglyceride emulsions. Pharmaceutical Research, 2000, 17, 1329-1332.	1.7	21
386	Characterization of oligonucleotide/lipid interactions in submicron cationic emulsions: influence of the cationic lipid structure and the presence of PEG-lipids. Biophysical Chemistry, 2001, 92, 169-181.	1.5	21
387	Novel microparticulate system made of poly(methylidene malonate 2.1.2). Biomaterials, 2001, 22, 2229-2238.	5.7	21
388	Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 612-620.	2.0	21
389	Self-Assembly of Polyisoprenoyl Gemcitabine Conjugates: Influence of Supramolecular Organization on Their Biological Activity. Langmuir, 2014, 30, 6348-6357.	1.6	21
390	Effects of Silencing the <i>RET/PTC1</i> Oncogene in Papillary Thyroid Carcinoma by siRNA-Squalene Nanoparticles With and Without Fusogenic Companion GALA-Cholesterol. Thyroid, 2014, 24, 327-338.	2.4	21
391	Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity. Journal of Controlled Release, 2019, 295, 223-236.	4.8	21
392	Efficient Loading and Controlled Release of Benzophenone-3 Entrapped into Self-Assembling Nanogels. Current Nanoscience, 2010, 6, 654-665.	0.7	21
393	Delivery of antisense oligonucleotides by means of pH-sensitive liposomes. Journal of Controlled Release, 1997, 48, 179-184.	4.8	20
394	Interfacial deposition of functionalized copolymers onto nanoemulsions produced by the solvent displacement method. Colloid and Polymer Science, 2001, 279, 784-792.	1.0	20
395	Antisense Oligonucleotide Nanocapsules Efficiently Inhibit EWS-Fli1 Expression in a Ewing's Sarcoma Model. Oligonucleotides, 2006, 16, 158-168.	2.7	20
396	A comprehensive study on the inclusion mechanism of benzophenone into supramolecular nanoassemblies prepared using two water-soluble associative polymers. Journal of Thermal Analysis and Calorimetry, 2009, 98, 57-64.	2.0	20

#	Article	IF	CITATIONS
397	"Squalenoylcurcumin―Nanoassemblies as Waterâ€Dispersible Drug Candidates with Antileishmanial Activity. ChemMedChem, 2015, 10, 411-418.	1.6	20
398	Colloidal properties of biodegradable nanoparticles influence interaction with amyloid-β peptide. Journal of Biotechnology, 2011, 156, 338-340.	1.9	19
399	Synthesis and Cytotoxic Activity of Selfâ€Assembling Squalene Conjugates of 3â€[(Pyrrolâ€2â€yl)methylidene]â€2,3â€dihydroâ€1 <i>H</i> â€indolâ€2â€one Anticancer Agents. European Jourr Organic Chemistry, 2015, 2015, 202-212.	nalæf	19
400	Desmoplastic Reaction in 3Dâ€Pancreatic Cancer Tissues Suppresses Molecular Permeability. Advanced Healthcare Materials, 2017, 6, 1700057.	3.9	19
401	Preparation and characterization of biodegradable poly(isobutylcyano acrylate) nanoparticles with the surface modified by the adsorption of proteins. Colloids and Surfaces B: Biointerfaces, 1995, 4, 349-356.	2.5	18
402	Title is missing!. Journal of Nanoparticle Research, 2003, 5, 365-371.	0.8	18
403	Consequences of ions and pH on the supramolecular organization of sphingomyelin and sphingomyelin/cholesterol bilayers. Chemistry and Physics of Lipids, 2008, 153, 119-129.	1.5	18
404	Simultaneous use of size-exclusion chromatography and photon correlation spectroscopy for the characterization of poly(lactic acid) nanoparticles. Journal of Chromatography A, 1994, 675, 129-139.	1.8	17
405	Cellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate). Journal of Controlled Release, 2005, 106, 209-213.	4.8	17
406	Busulfan loading into poly(alkyl cyanoacrylate) nanoparticles: Physico-chemistry and molecular modeling. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2006, 79B, 254-262.	1.6	17
407	Freeze-drying of squalenoylated nucleoside analogue nanoparticles. International Journal of Pharmaceutics, 2009, 381, 140-145.	2.6	17
408	Supramolecular organization of S12363-liposomes prepared with two different remote loading processes. Biochimica Et Biophysica Acta - Biomembranes, 2009, 1788, 926-935.	1.4	17
409	In-vitro evaluation of filaricidal activity of GABA and 1,3-dipalmitoyl-2-(4-aminobutyryl)glycerol HCI: a diglyceride prodrug. Journal of Pharmacy and Pharmacology, 2011, 41, 191-193.	1.2	17
410	New Formulation for the Delivery of Oligonucleotides Using "Clickable― siRNA-Polyisoprenoid-Conjugated Nanoparticles: Application to Cancers Harboring Fusion Oncogenes. Bioconjugate Chemistry, 2018, 29, 1961-1972.	1.8	17
411	Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides. Methods in Molecular Biology, 2018, 1727, 443-454.	0.4	17
412	Drug-Initiated Synthesis of Heterotelechelic Polymer Prodrug Nanoparticles for <i>in Vivo</i> Imaging and Cancer Cell Targeting. Biomacromolecules, 2019, 20, 2464-2476.	2.6	17
413	In VitroEvaluation of Nanoparticle Formulations Containing Gangliosides. Journal of Drug Targeting, 1994, 2, 53-59.	2.1	16
414	Study of the breakup under shear of a new thermally reversible water-in-oil-in-water (W/O/W) multiple emulsion. Pharmaceutical Research, 2001, 18, 689-693.	1.7	16

#	Article	IF	CITATIONS
415	Sustained delivery of growth factors from methylidene malonate 2.1.2-based polymers. Biomaterials, 2006, 27, 2609-2620.	5.7	16
416	siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Research, 2008, 36, 6944-6944.	6.5	16
417	Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. International Journal of Pharmaceutics, 2009, 379, 235-243.	2.6	16
418	A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. International Journal of Pharmaceutics, 2011, 414, 285-297.	2.6	16
419	Nanomedicine: From where are we coming and where are we going?. Journal of Controlled Release, 2019, 311-312, 319-321.	4.8	16
420	Therapeutic Opportunities in Neuroblastoma Using Nanotechnology. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 625-635.	1.3	16
421	Retrovirus budding may constitute a port of entry for drug carriers. Biochimica Et Biophysica Acta - Molecular Cell Research, 1996, 1310, 53-59.	1.9	15
422	Paraquat detoxication with multiple emulsions. International Journal of Pharmaceutics, 2009, 380, 142-146.	2.6	15
423	Squalene-Adenosine Nanoparticles: Ligands of Adenosine Receptors or Adenosine Prodrug?. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 144-151.	1.3	15
424	Surface Pressure and Surface Potential Studies of Poly(Isobutylcyanoacrylate)-Ampicillin Interactions at the Water-Air Interface. Journal of Bioactive and Compatible Polymers, 1989, 4, 110-123.	0.8	14
425	Strategies to Increase the Oral Bioavailability of Nucleoside Analogs. Current Medicinal Chemistry, 2009, 16, 1391-1399.	1.2	14
426	Combined antitumoral therapy with nanoassemblies of bolaform polyisoprenoyl paclitaxel/gemcitabine prodrugs. Polymer Chemistry, 2014, 5, 1662-1673.	1.9	14
427	Preactivated Oxazaphosphorines Designed for Isophosphoramide Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis and Proof of Concept. Journal of Medicinal Chemistry, 2015, 58, 705-717.	2.9	14
428	Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells. Scientific Reports, 2017, 7, 8353.	1.6	14
429	Capillary electrophoresis monitoring of the competitive adsorption of albumin onto the orosomucoid-coated polyisobutylcyanoacrylate nanoparticles. Electrophoresis, 1994, 15, 234-239.	1.3	13
430	Influence of surface properties on the inflammatory response to polymeric nanoparticles. Pharmaceutical Research, 1995, 12, 1385-1387.	1.7	13
431	In vitroandin vivoEvaluation of Poly(Methylidene Malonate 2.1.2) Microparticles Behavior for Oral Administration. Journal of Drug Targeting, 2001, 9, 141-153.	2.1	13
432	Cationic emulsions improves the delivery of oligonucleotides to leukemic P388/ADR cells in ascite. Journal of Controlled Release, 2003, 89, 473-482.	4.8	13

#	Article	IF	CITATIONS
433	Interfacial rheology as a tool to study the potential of cyclodextrin polymers to stabilize oil–water interfaces. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011, 69, 475-479.	1.6	13
434	Preparation and Characterization of Biocompatible Chitosan Nanoparticles for Targeted Brain Delivery of Peptides. Methods in Molecular Biology, 2012, 846, 321-332.	0.4	13
435	Effects of siRNA on RET/PTC3 Junction Oncogene in Papillary Thyroid Carcinoma: From Molecular and Cellular Studies to Preclinical Investigations. PLoS ONE, 2014, 9, e95964.	1.1	13
436	A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 165-173.	2.0	13
437	Preparation and in vivo studies of a new drug delivery system. Applied Biochemistry and Biotechnology, 1984, 10, 263-265.	1.4	12
438	N-methylation of anthracyclines modulates their cytotoxicity and pharmacokinetic in wild type and multidrug resistant cells. Biomedicine and Pharmacotherapy, 2003, 57, 301-308.	2.5	12
439	Nanoparticles against Alzheimer's disease: PEG–PACA nanoparticles are able to link the aβ-peptide and influence its aggregation kinetic. Journal of Controlled Release, 2010, 148, e112-e113.	4.8	12
440	Les nitriles et les amides bromcrotoniques III action de la Nâ^1⁄4Bromsuccinimide sur les butènes-nitriles. Bulletin Des Sociétés Chimiques Belges, 2010, 61, 253-260.	0.0	12
441	Nanomedicines and stroke: Toward translational research. Journal of Drug Delivery Science and Technology, 2015, 30, 278-299.	1.4	12
442	A Self-Assembling NHC-Pd-Loaded Calixarene as a Potent Catalyst for the Suzuki-Miyaura Cross-Coupling Reaction in Water. Molecules, 2020, 25, 1459.	1.7	12
443	(Poly-cyanoacrylate) nanomedicines for cancer and beyond: Lessons learned. Journal of Controlled Release, 2021, 334, 318-326.	4.8	12
444	Involvement of Macrophages in the Pathogenesis of Transmissible Spongiform Encephalopathies. Autoimmunity, 2002, 9, 19-27.	0.6	11
445	Effect of nanoparticles binding ß-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. International Journal of Nanomedicine, 2013, 8, 1335.	3.3	11
446	Replenishing reservoirs in vivo. Nature Nanotechnology, 2014, 9, 874-875.	15.6	11
447	Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide. Molecular Therapy - Nucleic Acids, 2016, 5, e301.	2.3	11
448	Elongated self-assembled nanocarriers: From molecular organization to therapeutic applications. Advanced Drug Delivery Reviews, 2021, 172, 127-147.	6.6	11
449	Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. International Journal of Pharmaceutics, 1998, 166, 117-120.	2.6	10
450	Monolayer studies on poly(isobutylcyanoacrylate)-ampicillin association. Journal of Pharmacy and Pharmacology, 2011, 39, 973-977.	1.2	10

#	Article	IF	CITATIONS
451	Influence of the nanoprecipitation conditions on the supramolecular structure of squalenoyled nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 96, 89-95.	2.0	10
452	Squalene versus cholesterol: Which is the best nanocarrier for the delivery to cells of the anticancer drug gemcitabine?. Comptes Rendus Chimie, 2018, 21, 974-986.	0.2	10
453	Stacking as a Key Property for Creating Nanoparticles with Tunable Shape: The Case of Squalenoyl-Doxorubicin. ACS Nano, 2019, 13, 12870-12879.	7.3	10
454	Squalene-based nanoparticles for the targeting of atherosclerotic lesions. International Journal of Pharmaceutics, 2020, 581, 119282.	2.6	10
455	A New Method to Isolate Polyalkylcyanoacrylate Nanoparticle Preparations. Journal of Drug Targeting, 1995, 3, 167-169.	2.1	9
456	Slow Delivery of the Selective Cholecystokinin Agonist pBC 264 into the Rat Nucleus Accumbens Using Microspheres. Journal of Neurochemistry, 2002, 67, 2417-2424.	2.1	9
457	Lipid onjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. Advanced Healthcare Materials, 2015, 4, 1015-1022.	3.9	9
458	PLGA-PEG-supported Pd Nanoparticles as Efficient Catalysts for Suzuki-Miyaura Coupling Reactions in Water. Chimia, 2016, 70, 252-257.	0.3	9
459	Adenosine and lipids: A forced marriage or a love match?. Advanced Drug Delivery Reviews, 2019, 151-152, 233-244.	6.6	9
460	Albumin-driven disassembly of lipidic nanoparticles: the specific case of the squalene-adenosine nanodrug. Nanoscale, 2020, 12, 2793-2809.	2.8	9
461	Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles. Bioconjugate Chemistry, 2021, 32, 782-793.	1.8	9
462	Investigation of squalene-doxorubicin distribution and interactions within single cancer cell using Raman microspectroscopy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 35, 102404.	1.7	9
463	Colloidal Carriers: A Promising Way to Treat Central Nervous System Diseases. Journal of Nanoneuroscience, 2009, 1, 17-34.	0.5	9
464	Polymeric Nanoparticles as Drug Carriers. , 2006, , 101-110.		9
465	Synthesis and aqueous organization of 1,3-dipalmitoyl-2-(4-aminobutyryl) glycerol·HCl: a diglyceride prodrug. Chemistry and Physics of Lipids, 1991, 59, 75-81.	1.5	8
466	Propidium-iodide-loaded polyalkylcyanoacrylate particles ?labelling conditions and loading capacity. Colloid and Polymer Science, 1991, 269, 147-152.	1.0	8
467	Retroviral Inhibition by Antisense Oligonucleotides Determined by Intracellular Stability. Antisense Research and Development, 1994, 4, 207-210.	3.3	8
468	Oral administration of peptides: Study of a glycerolipidic prodrug. International Journal of Pharmaceutics, 1995, 115, 45-52.	2.6	8

#	Article	IF	CITATIONS
469	Analysis of Serum Proteins by Micellar Electrokinetic Capillary Chromatography. Application to a Drug Carrier Evaluation. Journal of Liquid Chromatography and Related Technologies, 1996, 19, 3333-3353.	0.5	8
470	Oral absorption and tissue distribution of a new squalenoyl anticancer nanomedicine. Journal of Nanoparticle Research, 2008, 10, 887-891.	0.8	8
471	Biodegradable polymeric nanoformulation based on the antiprotozoal canthin-6-one. Journal of Nanoparticle Research, 2011, 13, 6737-6746.	0.8	8
472	Quantification of trimesic acid in liver, spleen and urine by high-performance liquid chromatography coupled to a photodiode-array detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2311-2314.	1.2	8
473	In vitro determination of the CYP 3A4 activity in rat hepatic microsomes by liquid-phase extraction and HPLC-photodiode array detection. Journal of Pharmacological and Toxicological Methods, 2012, 66, 29-34.	0.3	8
474	The role of solvent swelling in the self-assembly of squalene based nanomedicines. Soft Matter, 2015, 11, 4173-4179.	1.2	8
475	Synthesis of a deuterated probe for the confocal Raman microscopy imaging of squalenoyl nanomedicines. Beilstein Journal of Organic Chemistry, 2016, 12, 1127-1135.	1.3	8
476	Squalenoyl-gemcitabine/edelfosine nanoassemblies: Anticancer activity in pediatric cancer cells and pharmacokinetic profile in mice. International Journal of Pharmaceutics, 2020, 582, 119345.	2.6	8
477	Micro- and nanocarriers for pain alleviation. Advanced Drug Delivery Reviews, 2022, 187, 114359.	6.6	8
478	Theoretical and experimental study of beveled thyristor structures. Solid-State Electronics, 1979, 22, 967-971.	0.8	7
479	Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Journal of Microencapsulation, 2007, 24, 715-730.	1.2	7
480	Application of thermal analysis to the study of lipidic prodrug incorporation into nanocarriers. Journal of Thermal Analysis and Calorimetry, 2009, 98, 65-71.	2.0	7
481	Combinatorial Nanomedicine Made of Squalenoyl-Gemcitabine and Edelfosine for the Treatment of Osteosarcoma. Cancers, 2020, 12, 1895.	1.7	7
482	Gemcitabine lipid prodrug nanoparticles: Switching the lipid moiety and changing the fate in the bloodstream. International Journal of Pharmaceutics, 2021, 609, 121076.	2.6	7
483	Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release. Current Topics in Medicinal Chemistry, 2017, 17, .	1.0	7
484	Pharmacological manipulation of early PrPres accumulation in the spleen of scrapie-infected mice. , 2000, , 39-56.		7
485	The use of poly (isobutyl cyanoacrylate) nanoparticles with selected antifungal drugs. FEMS Microbiology Letters, 1987, 44, 413-416.	0.7	6
486	In vivo fate and immune pulmonary response after nasal administration of microspheres loaded with phosphorylcholine-thyroglobulin. International Journal of Pharmaceutics, 1999, 183, 73-79.	2.6	6

4

#	Article	IF	CITATIONS
487	Amphiphilic derivatives of dextran and related nanoparticles. Polymer Science - Series A, 2007, 49, 708-715.	0.4	6
488	Atomic pair distribution function (PDF) study of iron oxide nanoparticles in aqueous suspension. Journal of Materials Chemistry, 2009, 19, 6354.	6.7	6
489	Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies. International Journal of Pharmaceutics, 2014, 471, 75-82.	2.6	6
490	InÂvitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better. Biochimie, 2016, 130, 4-13.	1.3	6
491	Synthesis and Biopharmaceutical Characterization of Amphiphilic Squalenyl Derivative Based Versatile Drug Delivery Platform. Frontiers in Chemistry, 2020, 8, 584242.	1.8	6
492	New Poly(Methylidene Malonate 2.1.2) Nanoparticles: Recent Developments. , 1994, , 161-172.		6
493	Inhibition of the Friend Retrovirus by Antisense Oligonucleotides Annals of the New York Academy of Sciences, 1992, 660, 334-335.	1.8	5
494	Biocompatible poly(methylidene malonate)-made materials for pharmaceutical and biomedical applications. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 479-495.	2.0	5
495	Nanoencapsulation of antiviral nucleotide analogs. Journal of Drug Delivery Science and Technology, 2009, 19, 385-390.	1.4	5
496	Swelling of a Sponge Lipid Phase via Incorporation of a Nonionic Amphiphile: SANS and SAXS Studies. , 2011, , 1-6.		5
497	Turning Squalene into Cationic Lipid Allows a Delivery of siRNA in Cultured Cells. Nucleic Acid Therapeutics, 2015, 25, 121-129.	2.0	5
498	Decoration of Squalenoylâ€Gemcitabine Nanoparticles with Squalenylâ€Hydroxybisphosphonate for the Treatment of Bone Tumors. ChemMedChem, 2021, 16, 3730-3738.	1.6	5
499	Nanocapsules: Preparation, Characterization and Therapeutic Applications. , 2006, , 255-276.		5
500	Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles. , 1987, 33, 397-405.		5
501	Quantitative study of the interaction between polybutylcyanoacrylate nanoparticles and mouse peritoneal macrophages in culture. Journal De Pharmacie De Belgique, 1983, 38, 130-4.	0.2	5
502	Preparation and evaluation of alpha-phenyl-n-tert-butyl nitrone (PBN)-encapsulated chitosan and PEGylated chitosan nanoparticles. Die Pharmazie, 2009, 64, 436-9.	0.3	5
503	Nanomedicines and cell-based therapies for embryonal tumors of the nervous system. Journal of Controlled Release, 2022, 348, 553-571.	4.8	5

504 Porous Metal–Organic Frameworks as New Drug Carriers. , 2011, , 559-573.

#	Article	IF	CITATIONS
505	Quantification of tetramethyl-terephthalic acid in rat liver, spleen and urine matrices by liquid–liquid phase extraction and HPLC-photodiode array detection. Journal of Pharmaceutical and Biomedical Analysis, 2012, 67-68, 98-103.	1.4	4
506	Selective modification of a native protein in a patient tissue homogenate using palladium nanoparticles. Chemical Communications, 2019, 55, 15121-15124.	2.2	4
507	When drug nanocarriers miss their target: extracellular diffusion and cell uptake are not enough to be effective. Biomaterials Science, 2021, 9, 5407-5414.	2.6	4
508	Development of Novel Technologies for the Synthesis of Biodegradable Pegylated Nanoparticles. , 1998, , 225-239.		4
509	Adsorption of Allergen Extracts onto Colloidal Particles. Journal of Colloid and Interface Science, 1994, 166, 294-301.	5.0	3
510	Simultaneous quantification of preactivated ifosfamide derivatives and of 4-hydroxyifosfamide by high performance liquid chromatography–tandem mass spectrometry in mouse plasma and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 992, 30-35.	1.2	3
511	Supramolecular organization and biological interaction of squalenoyl siRNA nanoparticles. International Journal of Pharmaceutics, 2021, 609, 121117.	2.6	3
512	pH Sensitive Liposomes as Efficient Carriers for Intracellular Delivery of Oligonucleotides. , 1996, , 151-162.		3
513	Nanoparticles: Blood Components Interactions. , 2014, , 1-10.		3
514	Formulation of Didanosine Prodrugs into PEGylated Poly(alkyl cyanoacrylate) Nanoparticles and Uptake by Brain Endothelial Cells. Journal of Nanoneuroscience, 2009, 1, 174-183.	0.5	3
515	Polymeric Micro- and Nanoparticles as Drug Carriers. , 2001, , .		2
516	Oil/water "hand-bag like structures― how interfacial rheology can help to understand their formation?. Journal of Drug Delivery Science and Technology, 2005, 15, 3-9.	1.4	2
517	Development of micro- and nanosystems for drug delivery. Russian Journal of General Chemistry, 2008, 78, 2220-2229.	0.3	2
518	Formulation of glycerolipidic prodrugs into PEGylated liposomes for brain delivery. Journal of Drug Delivery Science and Technology, 2009, 19, 61-66.	1.4	2
519	X-ray microfluorescence for biodistribution studies of nanomedicines. International Journal of Pharmaceutics, 2017, 531, 343-349.	2.6	2
520	Ultrasound-triggered pain relief. Nature Biomedical Engineering, 2017, 1, 625-626.	11.6	2
521	Targetable Nanoparticles. , 1986, , 147-164.		2
522	Therapeutic Aspects of Liposomes. , 1990, , 133-165.		2

#	Article	IF	CITATIONS
523	Squalenoylation: A Novel Technology for Anticancer and Antibiotic Drugs with Enhanced Activity. , 2016, , 253-272.		2
524	Preparation and In Vivo Studies of a New Drug Delivery System. , 1984, , 263-265.		2
525	Avalanche multiplication factor and reverse current of Si p-n junctions. Physica Status Solidi A, 1976, 38, 123-129.	1.7	1
526	Liposomes their fate in vivo and their possible therapeutic use (1.V. route). Efficiency of liposome-entrapped ATP in cerebral ischemia. Phosphorus, Sulfur and Silicon and the Related Elements, 1993, 77, 109-112.	0.8	1
527	Nanoparticles for the Delivery of Peptides and Proteins. , 1994, , 153-159.		1
528	Doxorubicin-loaded nanoparticles shows increased cytotoxicity efficacy agains hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology, 2002, 36, 82.	1.8	1
529	Biodistribution and anticancer activity of a newvincaalkaloid encapsulated into long-circulating liposomes. Journal of Liposome Research, 2010, 20, 62-72.	1.5	1
530	Lipid-Based Anticancer Prodrugs. , 2010, , 291-328.		1
531	Nanomaterials: Applications in Drug Delivery. , 2013, , 131-151.		1
532	The Drug-Initiated Method: A Convenient Approach for the Synthesis of Efficient Polymer Prodrug Nanoparticles. ACS Symposium Series, 2015, , 257-272.	0.5	1
533	Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies. International Journal of Pharmaceutics, 2017, 532, 748-756.	2.6	1
534	Poly(Alkylcyanoacrylates). Surfactant Science, 2003, , .	0.0	1
535	SC16 stimulation of the mucosal immune response by a thyroglobulin-phosphorylcholine conjugate entrapped in PLA-GA microspheres. European Journal of Pharmaceutical Sciences, 1994, 2, 94.	1.9	0
536	Antisense oligonucleotides in cancerology. European Journal of Cancer, 1997, 33, S219.	1.3	0
537	Phospholipid/triglyceride mixtures: analysis and comparison of the solubilisation profiles. , 2004, , 139-142.		0
538	Solubility of triacylglycerols or stearylamine in phospholipid vesicles. , 2004, , 6-13.		0
539	Dossier: Drug delivery and drug efficacy. Biomedicine and Pharmacotherapy, 2004, 58, 141.	2.5	0
540	Special JDDST issue in honour of Prof. Dominique Duchêne. Journal of Drug Delivery Science and Technology, 2015, 30, 251-259.	1.4	0

IF # ARTICLE CITATIONS Trends in the development of oral anticoagulants. Therapeutic Delivery, 2015, 6, 685-703. 541 New Enkephalin Nanomedicines for Pain Alleviation, Overcoming the Side Effects of Morphine. , 2021, , 191-212. 542 0 Biology and the Environment., 2007,, 695-715. 543 La « squalénisation » : un exemple de conception de nanomédicaments anticancéreux et antiviraux. Bulletin De L'Academie Nationale De Medecine, 2009, 193, 663-674. 544 0.0 0 Poly (Alkylcyanoacrylates)., 1998,,. 545

P COUVREUR